Progress of artificial pancreas devices towards clinical use: The first outpatient studies

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 22, Issue 2, 2015, Pages 106-111

  Russell, Steven J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

artificial pancreas; bionic pancreas; continuous glucose monitoring; glucagon insulin; sensor augmented pump

Indexed keywords

GLUCOSE; INSULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ANTIDIABETIC ACTIVITY; ARTIFICIAL PANCREAS; AUTOMATION; EXERCISE; GESTATION PERIOD; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN SENSITIVITY; INSULIN TREATMENT; OUTPATIENT CARE; PHYSICAL ACTIVITY; REVIEW; SELF CARE; ADVERSE EFFECTS; AMBULATORY CARE; BLOOD; BLOOD GLUCOSE MONITORING; CIRCADIAN RHYTHM; DEVICES; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; LIFESTYLE; MASS COMMUNICATION; METABOLISM; RISK FACTOR; TREATMENT OUTCOME;

AMBULATORY CARE; BIOMARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DIFFUSION OF INNOVATION; EQUIPMENT DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; LIFE STYLE; PANCREAS, ARTIFICIAL; RISK FACTORS; TREATMENT OUTCOME;

EID: 84926391833     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000142     Document Type: Review

References (39)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
2. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287:2563-2594.
3. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
4. Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015; 313:45-53.
5. Petitti DB, Klingensmith J, Bell RA, et al., SEARCH for Diabetes in Youth Study Group. Glycemic control in youth with diabetes: The SEARCH for Diabetes in Youth Study. J Pediatr 2009; 155:668-672.
6. Tamborlane RW, Bergenstal RM, Miller KM, et al., T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012; 97:4383-4389.
7. Wood JR, Miller KM, Maahs DM, et al., T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 2013; 36:2035-2037.
8. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes 1997; 46:271-286.
9. Leese GP, Wang J, Broomhall J. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26:1176-1180.
10. Cengiz E, Xing D, Wong JC, et al., T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. Pediatr Diabetes 2013; 14:447-454.
11. Weinstock RS, Xing D, Maahs DM, et al., T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013; 98:3411-3419.
12. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26:1902-1912.
13. Strandberg RB, Graue M, Wentzel-Larsen T, et al. Relationships of diabetesspecific emotional distress, depression, anxiety, and overall well being with HbA1c in adult persons with type 1 diabetes. J Psychosom Res 2014; 77:174-179.
14. Zoffmann V, Vistisen D, Due-Christensen M. A cross-sectional study of glycaemic control, complications and psychosocial functioning among 18- to 35-year-old adults with type 1 diabetes. Diabet Med 2014; 31:493-499.
15. Lindstrom C, Aman J, Norberg AL. Parental burnout in relation to sociodemographic, psychosocial and personality factors as well as disease duration and glycaemic control in children with Type 1 diabetes mellitus. Acta Paediatr 2011; 100:1011-1017.
16. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359:1464-1476.
17. Langendam M1, Luijf YM, Hooft L, et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012; 18:CD008101.
18. Doyle FJ, Huyett LM, Lee JB, et al. Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care 2014; 37:1191-1197.
19. Peyser T, Dassau E, Breton M, Skyler JS. The artificial pancreas: current status and future prospects in the management of diabetes. Ann NY Acad Sci 2014; 1311:102-123.
20. Bergenstal RM, Klonoff DC, Garg SK, et al., ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369:224-232.
21. Maahs DM, Calhoun P, Buckingham BA, et al., In Home Closed Loop Study Group. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care 2014; 37:1-7.
22. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013; 368:824-833.
23. Nimri R, Muller I, Atlas E, et al. Night glucose control with MD-logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2014; 15:91-99.
24. Nimri R, Muller I, Atlas E, et al. MD-logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 2014; 37:3025-3032.
25. Hovorka R, Elleri D, Thabit J. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2014; 37:1204-1211.
26. Thabit H, Lubina-Solomon A, Stadler M, et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol 2014; 2:701-709.
27. Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 2014; 37:1789-1796.
28. Leelarathna L, Dellweg S, Mader JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 2014; 37:1931-1937.
29. van Bon AC, Luijf YM, Koebrugge R, et al. Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diab Tech Ther 2014; 16:131-136.
30. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014; 371:313-325.
31. Quesada I, Tuduri? E, Ripoll C, Nadal A. Physiology of the pancreatic a-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 2008; 199:5-19.
32. Bolli G, De Feo P, Compagnucci P, et al. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus: interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 1983; 32:134-141.
33. Siafarika A, Johnston RJ, Bulsara MK. Early loss of the glucagon response to hypoglycemia in adolescents with type 1 diabetes. Diabetes Care 2012; 35:1757-1762.
34. Kudva YC, Carter RE, Cobelli C, et al. Closed-loop artificial pancreas systems: physiological input to enhance next generation devices. Diabetes Care 2014; 37:1184-1190.
35. Bellin MD, Parazzoli S, Oseid E, et al. Defective glucagon secretion during hypoglycemia after intrahepatic but not nonhepatic islet autotransplantation. Am J Transplant 2014; 14:1880-1886.
36. Schultes B, Jauch-Chara K, Gais S, et al. Defective awakening response to nocturnal hypoglycemia in patients with type 1 diabetes mellitus. PLoS Med 2007; 4:e69.
37. Buckingham B, Block J, Burdick J, et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther 2005; 7:440-447.
38. Newswanger B, Ammons S, Phadnis N, et al. Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. J Diabetes Sci Tech 2015; 9:24-33.
39. Haidar A, Legault L, Messier V, et al. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diab Endocrinol 2015; 3:17-26.